Abilify Related Published Studies
Well-designed clinical trials related to Abilify (Aripiprazole)
A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. [2008.07]
Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. [2008.05]
Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. [2008.05]
Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study. [2008.05]
Effects of aripiprazole on subjective and physiological responses to alcohol. [2008.04]
Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. [2008.04]
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. [2008.03.26]
Aripiprazole Augmentation in Clozapine-Treated Patients With Refractory Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial. [2008.03.18]
Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. [2007.12]
Aripiprazole in juvenile bipolar disorder comorbid with attention-deficit/hyperactivity disorder: an open clinical trial. [2007.10]
An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression. [2007.10]
Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. [2007.10]
A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA). [2007.10]
A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. [2007.10]
Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. [2007.09]
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. [2007.09]
A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. [2007.06.05]
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. [2007.06]
Aripiprazole: pharmacology and evidence in bipolar disorder. [2007.05]
Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. [2007.05]
Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up. [2007.05]
An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression. [2007.03.06]
Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. [2007.02]
Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. [2007.01]
Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. [2007]
The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance. [2007]
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. [2006.12]
Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. [2006.11.16]
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. [2006.10.21]
Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. [2006.07]
Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. [2006.05]
A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). [2006.05]
A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. [2006.04]
An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. [2006.02]
Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. [2006.01.09]
An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. [2006]
Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. [2005.10]
Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. [2005.09]
Aripiprazole, a novel atypical antipsychotic drug. [2004.02]
Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. [2004.02]
A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. [2004]
Aripiprazole. [2003.12.01]
Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. [2003.12]
Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. [2003.09]
A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. [2003.09]
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. [2003.07]
Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. [2003.04]
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. [2002.09]
Spontaneous brain magnetic activity in schizophrenia patients treated with aripiprazole. [1998]
Well-designed clinical trials possibly related to Abilify (Aripiprazole)
Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. [2008.05]
Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. [2008.04]
A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. [2008.02]
A Review of Sensitivity and Tolerability of Antipsychotics in Patients With Bipolar Disorder or Schizophrenia: Focus on Somnolence. [2008.01.16]
Pathophysiology and treatment of psychosis in Parkinson's disease: a review. [2008]
Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. [2007.11]
Efficacy and Safety of Donepezil in Patients with Schizophrenia or Schizoaffective Disorder: Significant Placebo/Practice Effects in a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. [2007.07.11]
Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. [2007.06]
Are There Any Differences in the Efficacy among Second Generation Antipsychotics in the Treatment of Schizophrenia and Related Disorders? [2007.04]
Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. [2006.09]
Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. [2006.04]
Extrapyramidal side effects with atypical neuroleptics in bipolar disorder. [2006.03]
Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. [2005.12]
Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. [2005.10.19]
Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. [2005.09.15]
Other research related to Abilify (Aripiprazole)
Effect of aripiprazole on self-reported anhedonia in bipolar depressed patients. [2008.10.29]
Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. [2008.10.28]
Aripiprazole monotherapy in the treatment of acute bipolar I mania: A randomized, double-blind, placebo- and lithium-controlled study. [2008.10.02]
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder. [2008.10.02]
A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering. [2008.10]
Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. [2008.09.30]
Aripiprazole in the pharmacotherapy of Gilles de la Tourette syndrome in adult patients. [2008.09.11]
Favourable results in treatment-resistant schizophrenic patients under combination of aripiprazole with clozapine. [2008.07.29]
Aripiprazole versus typical antipsychotic drugs for schizophrenia. [2008.07.16]
A Non-randomized, Open Study with Aripiprazole and Ziprasidone for the Treatment of Aggressive Behavior in Youth in a Community Clinic. [2008.07.03]
A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. [2008.07]
The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Second Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. [2008.04]
Use of Aripiprazole in treatment resistant schizophrenia. [2008.02.28]
Effects of Aripiprazole on Subjective and Physiological Responses to Alcohol. [2008.02.08]
Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. [2008.02]
A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. [2008.02]
Taq1A polymorphism in the dopamine D2 receptor gene predicts brain metabolic response to aripiprazole in healthy male volunteers. [2008.02]
Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. [2008]
Criteria for Defining Symptomatic and Sustained Remission in Bipolar I Disorder: a Post-Hoc Analysis of a 26-Week Aripiprazole Study (Study CN138-010). [2008]
Clinical trials with a new atypical antipsychotic (Aripiprazole): gender specific information analysis. [2008]
A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. [2007.12]
Aripiprazole: effectiveness and safety under naturalistic conditions. [2007.12]
Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. [2007.12]
Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. [2007.11]
Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. [2007.11]
Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. [2007.11]
Augmentation of aripiprazole with low-dose clozapine. [2007.11]
Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. [2007.10]
Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. [2007.10]
Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. [2007.09.26]
Usefulness of the dopamine system-stabilizer aripiprazole for reducing morphine-induced emesis. [2007.09.10]
Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline. [2007.09]
An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. [2007.09]
Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. [2007.09]
Tolerability and efficacy of aripiprazole in a case of psychotic anorexia nervosa comorbid with epilepsy and chronic renal failure. [2007.09]
Agitation associated with aripiprazole initiation. [2007.09]
Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial. [2007.08]
|
